<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC6843332/results/search/drugs/results.xml">
  <result pre="resistance in immunocompromised persons [22]. The nucleoside analogues acyclovir and" exact="ganciclovir" post="are the standard therapy for HHV-1 and CMV, respectively"/>
  <result pre="the viral kinase pUL97 and polymerase pUL54 mediate resistance to" exact="ganciclovir" post="and valganciclovir [25]. The prevalence of resistance against acyclovir"/>
  <result pre="kinase pUL97 and polymerase pUL54 mediate resistance to ganciclovir and" exact="valganciclovir" post="[25]. The prevalence of resistance against acyclovir is 5%"/>
  <result pre="marrow transplant patients [26], whereas the incidence of resistance to" exact="ganciclovir" post="is 5–10% in organ transplant recipients [27] and 40–50%"/>
  <result pre="acyclovir are typically cross-resistant to thymidine kinase-dependent drugs such as" exact="penciclovir" post="and famciclovir. They also may be cross-resistant to polymerase"/>
  <result pre="also may be cross-resistant to polymerase dependent drugs, foscarnet or" exact="cidofovir" post="[26]. Ganciclovir-resistant strains also have shown cross resistance to"/>
  <result pre="also have shown cross resistance to second-line treatments foscarnet and" exact="cidofovir" post="[28]. Targeting the DNA polymerase and thymidine kinase, while"/>
  <result pre="integrase inhibitor, exhibits efficiency against herpes viruses. The effect of" exact="raltegravir" post="on herpes viruses is attributed to an inhibition of"/>
  <result pre="as the HIV integrase [31]. Recently however, drug resistance to" exact="raltegravir" post="has been traced to HHV-1 UL42 coding for the"/>
  <result pre="not a part of the terminase, it was determined that" exact="raltegravir" post="likely inhibits DNA replication through the polymerase accessory factor"/>
  <result pre="analyzed, which may explain the resistance that has emerged against" exact="raltegravir" post="and acyclovir, respectively. Since pUL15 is one of the"/>
  <result pre="pathogenic virusesAntimicrob. Agents Chemother.2012561135113710.1128/AAC.05908-1122106211 45.Caruso BrownA.E.CohenM.N.TongS.BravermanR.S.RooneyJ.F.GillerR.LevinM.J.Pharmacokinetics and safety of intravenous" exact="cidofovir" post="for life-threatening viral infections in pediatric hematopoietic stem cell"/>
 </snippets>
</snippetsTree>
